Heme oxygenase-1 in neovascularisation: A diabetic perspective

Summary

Neovascularisation is crucial both for physiological processes, like development, wound healing, tissue regeneration, hair growth or menstrual cycle, and for pathological states, such as tumour progression, retinopathy and psoriasis. Blood vessel formation is orchestrated by numerous pro-angiogenic and anti-angiogenic factors, acting together to keep tight rein on this complicated, desirable but also dangerous process. One of the proteins important for neovascularisation is heme oxygenase-1 (HO-1), an enzyme degrading heme. This review focuses on the role of HO-1 in angiogenesis and vasculogenesis, having a closer look at the significance of this system in diabetes.

Keywords

Heme oxygenase-1 - neovascularisation - diabetes - wound healing - endothelial progenitor cells

• References

• 1 Galbraith R. Heme oxygenase: who needs it?. Proc Soc Exp Biol Med 1999; 222: 299-305.
• 2 Balla J, Jacob HS, Balla G. et al. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci USA 1993; 90: 9285-9289.
• 3 Fontecave M, Pierre JL. Iron: metabolism, toxicity and therapy. Biochimie 1993; 75: 767-773.
• 4 Hill-Kapturczak N, Chang SH, Agarwal A. Heme oxygenase and the kidney. DNA Cell Biol 2002; 21: 307-321.
• 5 Maines MD, Trakshel GM, Kutty RK. Characterization of two constitutive forms of rat liver microsomal heme oxygenase. Only one molecular species of the enzyme is inducible. J Biol Chem 1986; 261: 411-419.
• 6 McCoubrey Jr WK, Ewing JF, Maines MD. Human heme oxygenase-2: characterization and expression of a full-length cDNA and evidence suggesting that the two HO-2 transcripts may differ by choice of polyadenylation signal. Arch Biochem Biophys 1992; 295: 13-20.
• 7 Maines MD, Kappas A. Enzymatic oxidation of cobalt protoporphyrin IX: observations on the mechanism of heme oxygenase action. Biochemistry 1977; 16: 419-423.
• 8 Maines MD. Bile pigments: newcomers to the cell signaling arena. Toxicol Sci 2003; 71: 9-10.
• 9 Converso DP, Taille C, Carreras MC. et al. HO-1 is located in liver mitochondria and modulates mitochondrial heme content and metabolism. FASEB J 2006; 20: 1236-1238.
• 10 Kim HP, Wang X, Galbiati F. et al. Caveolae compartmentalization of heme oxygenase-1 in endothelial cells. FASEB J 2004; 18: 1080-1089.
• 11 Lin Q, Weis S, Yang G. et al. Heme oxygenase-1 protein localizes to the nucleus and activates transcription factors important in oxidative stress. J Biol Chem 2007; 282: 20621-20633.
• 12 Loboda A, Jazwa A, Grochot-Przeczek A. et al. Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 2008; 10: 1767-1812.
• 13 Deshane J, Wright M, Agarwal A. Heme oxygenase-1 expression in disease states. Acta Biochim Pol 2005; 52: 273-284.
• 14 Desbuards N, Rochefort GY, Schlecht D. et al. Heme oxygenase-1 inducer hemin prevents vascular thrombosis. Thromb Haemost 2007; 98: 614-620.
• 15 Dulak J, Jozkowicz A. Carbon monoxide -- a “new” gaseous modulator of gene expression. Acta Biochim Pol 2003; 50: 31-47.
• 16 Graser T, Vedernikov YP, Li DS. Study on the mechanism of carbon monoxide induced endothelium-independent relaxation in porcine coronary artery and vein. Biomed Biochim Acta 1990; 49: 293-296.
• 17 Thorup C, Jones CL, Gross SS. et al. Carbon monoxide induces vasodilation and nitric oxide release but suppresses endothelial NOS. Am J Physiol 1999; 277: F882-F889.
• 18 Brune B, Ullrich V. Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol 1987; 32: 497-504.
• 19 Foresti R, Motterlini R. The heme oxygenase pathway and its interaction with nitric oxide in the control of cellular homeostasis. Free Radic Res 1999; 31: 459-475.
• 20 Brouard S, Otterbein LE, Anrather J. et al. Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis. J Exp Med 2000; 192: 1015-1026.
• 21 Liu XM, Chapman GB, Peyton KJ. et al. Carbon monoxide inhibits apoptosis in vascular smooth muscle cells. Cardiovasc Res 2002; 55: 396-405.
• 22 Petrache I, Otterbein LE, Alam J. et al. Heme oxygenase-1 inhibits TNF-alpha-induced apoptosis in cultured fibroblasts. Am J Physiol Lung Cell Mol Physiol 2000; 278: L312-L319.
• 23 Chae HJ, Chin HY, Lee GY. et al. Carbon monoxide and nitric oxide protect against tumor necrosis factor-alpha-induced apoptosis in osteoblasts: HO-1 is necessary to mediate the protection. Clin Chim Acta 2006; 365: 270-278.
• 24 Gunther L, Berberat PO, Haga M. et al. Carbon monoxide protects pancreatic beta-cells from apoptosis and improves islet function/survival after transplantation. Diabetes 2002; 51: 994-999.
• 25 Otterbein LE, Mantell LL, Choi AM. Carbon monoxide provides protection against hyperoxic lung injury. Am J Physiol 1999; 276: L688-L694.
• 26 Jozkowicz A, Huk I, Nigisch A. et al. Heme oxygenase and angiogenic activity of endothelial cells: stimulation by carbon monoxide and inhibition by tin protoporphyrin-IX. Antioxid Redox Signal 2003; 5: 155-162.
• 27 Li Volti G, Sacerdoti D, Sangras B. et al. Carbon monoxide signaling in promoting angiogenesis in human microvessel endothelial cells. Antioxid Redox Signal 2005; 7: 704-710.
• 28 Dulak J, Jozkowicz A, Foresti R. et al. Heme oxygenase activity modulates vascular endothelial growth factor synthesis in vascular smooth muscle cells. Antioxid Redox Signal 2002; 4: 229-240.
• 29 Jozkowicz A, Dulak J. Effects of protoporphyrins on production of nitric oxide and expression of vascular endothelial growth factor in vascular smooth muscle cells and macrophages. Acta Biochim Pol 2003; 50: 69-79.
• 30 Jozkowicz A, Huk I, Nigisch A. et al. Effect of prostaglandin-J(2) on VEGF synthesis depends on the induction of heme oxygenase-1. Antioxid Redox Signal 2002; 4: 577-585.
• 31 Balla G, Jacob HS, Balla J. et al. Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 1992; 267: 18148-18153.
• 32 Eisenstein RS, Garcia-Mayol D, Pettingell W. et al. Regulation of ferritin and heme oxygenase synthesis in rat fibroblasts by different forms of iron. Proc Natl Acad Sci USA 1991; 88: 688-692.
• 33 Baranano DE, Wolosker H, Bae BI. et al. A mammalian iron ATPase induced by iron. J Biol Chem 2000; 275: 15166-15173.
• 34 Otterbein LE, Soares MP, Yamashita K. et al. Heme oxygenase-1: unleashing the protective properties of heme. Trends Immunol 2003; 24: 449-455.
• 35 Stocker R, Yamamoto Y, McDonagh AF. et al. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046.
• 36 Baranano DE, Rao M, Ferris CD. et al. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002; 99: 16093-16098.
• 37 Dudnik LB, Khrapova NG. Characterization of bilirubin inhibitory properties in free radical oxidation reactions. Membr Cell Biol 1998; 12: 233-240.
• 38 Asad SF, Singh S, Ahmad A. et al. Prooxidant and antioxidant activities of bilirubin and its metabolic precursor biliverdin: a structure-activity study. Chem Biol Interact 2001; 137: 59-74.
• 39 Maghzal GJ, Leck MC, Collinson E. et al. Limited role for the bilirubin-biliverdin redox amplification cycle in the cellular antioxidant protection by biliverdin reductase. J Biol Chem 2009; 284: 29251-29259.
• 40 Poss KD, Tonegawa S. Heme oxygenase 1 is required for mammalian iron reutilization. Proc Natl Acad Sci USA 1997; 94: 10919-10924.
• 41 Poss KD, Tonegawa S. Reduced stress defense in heme oxygenase 1-deficient cells. Proc Natl Acad Sci USA 1997; 94: 10925-10930.
• 42 Yachie A, Niida Y, Wada T. et al. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J Clin Invest 1999; 103: 129-135.
• 43 Kazemi S, Wenzel D, Kolossov E. et al. Differential role of bFGF and VEGF for vasculogenesis. Cell Physiol Biochem 2002; 12: 55-62.
• 44 Di Stefano R, Barsotti MC, Melillo E. et al. The prostacyclin analogue iloprost increases circulating endothelial progenitor cells in patients with critical limb ischemia. Thromb Haemost 2008; 100: 871-877.
• 45 Cesari F, Sofi F, Caporale R. et al. Relationship between exercise capacity, endothelial progenitor cells and cytochemokines in patients undergoing cardiac rehabilitation. Thromb Haemost 2009; 101: 521-526.
• 46 Garcia-Barros M, Paris F, Cordon-Cardo C. et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-1159.
• 47 Asahara T, Masuda H, Takahashi T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 1999; 85: 221-228.
• 48 Ergun S, Tilki D, Hohn HP. et al. Potential implications of vascular wall resident endothelial progenitor cells. Thromb Haemost 2007; 98: 930-939.
• 49 He T, Peterson TE, Katusic ZS. Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol Heart Circ Physiol 2005; 289: H968-H972.
• 50 Urbich C, Aicher A, Heeschen C. et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005; 39: 733-742.
• 51 Santo SD, Tepper OM, von Ballmoos MW. et al. Cell-based therapy facilitates venous thrombus resolution. Thromb Haemost 2009; 101: 460-464.
• 52 Barzelay A, Ben-Shoshan J, Entin-Meer M. et al. A potential role for islet-1 in post-natal angiogenesis and vasculogenesis. Thromb Haemost 2010; 103: 188-197.
• 53 Dulak J, Deshane J, Jozkowicz A. et al. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008; 117: 231-241.
• 54 Cisowski J, Loboda A, Jozkowicz A. et al. Role of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 knockout. Biochem Biophys Res Commun 2005; 326: 670-676.
• 55 Lin HH, Chen YH, Yet SF. et al. After vascular injury, heme oxygenase-1/carbon monoxide enhances re-endothelialization via promoting mobilization of circulating endothelial progenitor cells. J Thromb Haemost 2009; 7: 1401-1408.
• 56 Zeng B, Chen H, Zhu C. et al. Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance. Eur J Cardiothorac Surg 2008; 34: 850-856.
• 57 Jazwa A, Loboda A, Golda S. et al. Effect of heme and heme oxygenase-1 on vascular endothelial growth factor synthesis and angiogenic potency of human keratinocytes. Free Radic Biol Med 2006; 40: 1250-1263.
• 58 Suzuki M, Iso-o N, Takeshita S. et al. Facilitated angiogenesis induced by heme oxygenase-1 gene transfer in a rat model of hindlimb ischemia. Biochem Biophys Res Commun 2003; 302: 138-143.
• 59 Was H, Cichon T, Smolarczyk R. et al. Overexpression of heme oxygenase-1 in murine melanoma: increased proliferation and viability of tumor cells, decreased survival of mice. Am J Pathol 2006; 169: 2181-2198.
• 60 Sengupta S, Sellers LA, Matheson HB. et al. Thymidine phosphorylase induces angiogenesis in vivo and in vitro: an evaluation of possible mechanisms. Br J Pharmacol 2003; 139: 219-231.
• 61 Sasaki T, Yoshida K, Kondo H. et al. Heme oxygenase-1 accelerates protumoral effects of nitric oxide in cancer cells. Virchows Arch 2005; 446: 525-531.
• 62 Hirai K, Sasahira T, Ohmori H. et al. Inhibition of heme oxygenase-1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice. Int J Cancer 2007; 120: 500-505.
• 63 Devesa I, Ferrandiz ML, Guillen I. et al. Potential role of heme oxygenase-1 in the progression of rat adjuvant arthritis. Lab Invest 2005; 85: 34-44.
• 64 Cudmore M, Ahmad S, Al-Ani B. et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
• 65 Lin HH, Chen YH, Chang PF. et al. Heme oxygenase-1 promotes neovascularization in ischemic heart by coinduction of VEGF and SDF-1. J Mol Cell Cardiol 2008; 45: 44-55.
• 66 Deshane J, Chen S, Caballero S. et al. Stromal cell-derived factor 1 promotes angiogenesis via a heme oxygenase 1-dependent mechanism. J Exp Med 2007; 204: 605-618.
• 67 Krause M, Dent EW, Bear JE. et al. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 2003; 19: 541-564.
• 68 Li Calzi S, Purich DL, Chang KH. et al. Carbon monoxide and nitric oxide mediate cytoskeletal reorganization in microvascular cells via vasodilator-stimulated phosphoprotein phosphorylation: evidence for blunted responsiveness in diabetes. Diabetes 2008; 57: 2488-2494.
• 69 Tongers J, Knapp JM, Korf M. et al. Haeme oxygenase promotes progenitor cell mobilization, neovascularization, and functional recovery after critical hindlimb ischaemia in mice. Cardiovasc Res 2008; 78: 294-300.
• 70 Bussolati B, Mason JC. Dual role of VEGF-induced heme-oxygenase-1 in angio-genesis. Antioxid Redox Signal 2006; 8: 1153-1163.
• 71 Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29: 10-14.
• 72 Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L.
• 73 Frank S, Hubner G, Breier G. et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem 1995; 270: 12607-12613.
• 74 Grochot-Przeczek A, Lach R, Mis J. et al. Heme oxygenase-1 accelerates cutaneous wound healing in mice. PLoS One 2009; 4: e5803.
• 75 Altavilla D, Saitta A, Cucinotta D. et al. Inhibition of lipid peroxidation restores impaired vascular endothelial growth factor expression and stimulates wound healing and angiogenesis in the genetically diabetic mouse. Diabetes 2001; 50: 667-674.
• 76 Galiano RD, Tepper OM, Pelo CR. et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol 2004; 164: 1935-1947.
• 77 Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impaired db/db mice. J Exp Med 1990; 172: 245-251.
• 78 Wetzler C, Kampfer H, Stallmeyer B. et al. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J Invest Dermatol 2000; 115: 245-253.
• 79 Darby IA, Bisucci T, Hewitson TD. et al. Apoptosis is increased in a model of diabetes-impaired wound healing in genetically diabetic mice. Int J Biochem Cell Biol 1997; 29: 191-200.
• 80 Lorenzi M, Nordberg JA, Toledo S. High glucose prolongs cell-cycle traversal of cultured human endothelial cells. Diabetes 1987; 36: 1261-1267.
• 81 Baumgartner-Parzer SM, Wagner L, Pettermann M. et al. High-glucose--triggered apoptosis in cultured endothelial cells. Diabetes 1995; 44: 1323-1327.
• 82 Zou MH, Shi C, Cohen RA. High glucose via peroxynitrite causes tyrosine nitration and inactivation of prostacyclin synthase that is associated with thromboxane/prostaglandin H(2) receptor-mediated apoptosis and adhesion molecule expression in cultured human aortic endothelial cells. Diabetes 2002; 51: 198-203.
• 83 Lorenzi M, Cagliero E, Toledo S. Glucose toxicity for human endothelial cells in culture. Delayed replication, disturbed cell cycle, and accelerated death. Diabetes 1985; 34: 621-627.
• 84 Curcio F, Ceriello A. Decreased cultured endothelial cell proliferation in high glucose medium is reversed by antioxidants: new insights on the pathophysiological mechanisms of diabetic vascular complications. In Vitro Cell Dev Biol 1992; 28A: 787-790.
• 85 Hayashi K, Haneda M, Koya D. et al. Enhancement of glomerular heme oxygenase-1 expression in diabetic rats. Diabetes Res Clin Pract 2001; 52: 85-96.
• 86 Cukiernik M, Mukherjee S, Downey D. et al. Heme oxygenase in the retina in diabetes. Curr Eye Res 2003; 27: 301-308.
• 87 Farhangkhoee H, Khan ZA, Mukherjee S. et al. Heme oxygenase in diabetes-induced oxidative stress in the heart. J Mol Cell Cardiol 2003; 35: 1439-1448.
• 88 Lundquist I, Alm P, Salehi A. et al. Carbon monoxide stimulates insulin release and propagates Ca2+ signals between pancreatic beta-cells. Am J Physiol Endocrinol Metab 2003; 285: E1055-E1063.
• 89 Ishida H, Takizawa M, Ozawa S. et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism 2004; 53: 488-494.
• 90 Quan S, Kaminski PM, Yang L. et al. Heme oxygenase-1 prevents superoxide anion-associated endothelial cell sloughing in diabetic rats. Biochem Biophys Res Commun 2004; 315: 509-516.
• 91 Mace KA, Yu DH, Paydar KZ. et al. Sustained expression of Hif-1alpha in the diabetic environment promotes angiogenesis and cutaneous wound repair. Wound Repair Regen 2007; 15: 636-645.
• 92 da Silva JL, Stoltz RA, Dunn MW. et al. Diminished heme oxygenase-1 mRNA expression in RPE cells from diabetic donors as quantitated by competitive RT/PCR. Curr Eye Res 1997; 16: 380-386.
• 93 Exner M, Minar E, Wagner O. et al. The role of heme oxygenase-1 promoter polymorphisms in human disease. Free Radic Biol Med 2004; 37: 1097-1104.
• 94 Yamada N, Yamaya M, Okinaga S. et al. Microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with susceptibility to emphysema. Am J Hum Genet 2000; 66: 187-195.
• 95 Chen YH, Lin SJ, Lin MW. et al. Microsatellite polymorphism in promoter of heme oxygenase-1 gene is associated with susceptibility to coronary artery disease in type 2 diabetic patients. Hum Genet 2002; 111: 1-8.
• 96 Endler G, Exner M, Schillinger M. et al. A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. Thromb Haemost 2004; 91: 155-161.
• 97 Chen YH, Chau LY, Chen JW. et al. Serum bilirubin and ferritin levels link heme oxygenase-1 gene promoter polymorphism and susceptibility to coronary artery disease in diabetic patients. Diabetes Care 2008; 31: 1615-1620.
• 98 Song F, Li X, Zhang M. et al. Association between heme oxygenase-1 gene promoter polymorphisms and type 2 diabetes in a Chinese population. Am J Epidemiol 2009; 170: 747-756.
• 99 Wysocki AB. Wound fluids and the pathogenesis of chronic wounds. J Wound Ostomy Continence Nurs 1996; 23: 283-290.
• 100 Wu SC, Driver VR, Wrobel JS. et al. Foot ulcers in the diabetic patient, prevention and treatment. Vasc Health Risk Manag 2007; 3: 65-76.
• 101 Dulak J, Tomala K, Loboda A. et al. Nitric oxide-dependent synthesis of vascular endothelial growth factor is impaired by high glucose. Life Sci 2004; 75: 2573-2586.
• 102 Abraham NG, Rezzani R, Rodella L. et al. Overexpression of human heme oxygenase-1 attenuates endothelial cell sloughing in experimental diabetes. Am J Physiol Heart Circ Physiol 2004; 287: H2468-H2477.
• 103 Abraham NG, Kushida T, McClung J. et al. Heme oxygenase-1 attenuates glucose-mediated cell growth arrest and apoptosis in human microvessel endothelial cells. Circ Res 2003; 93: 507-514.
• 104 Chen S, Khan ZA, Barbin Y. et al. Pro-oxidant role of heme oxygenase in mediating glucose-induced endothelial cell damage. Free Radic Res 2004; 38: 1301-1310.
• 105 Rodella LF, Vanella L, Peterson SJ. et al. Heme oxygenase-derived carbon mon-oxide restores vascular function in type 1 diabetes. Drug Metab Lett 2008; 2: 290-300.
• 106 L’Abbate A, Neglia D, Vecoli C. et al. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. Am J Physiol Heart Circ Physiol 2007; 293: H3532-H3541.
• 107 Jung TW, Lee JY, Shim WS. et al. Adiponectin protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity. Biochem Pharmacol 2006; 72: 616-623.
• 108 Hopkins TA, Ouchi N, Shibata R. et al. Adiponectin actions in the cardiovascular system. Cardiovasc Res 2007; 74: 11-18.
• 109 Bahia L, Aguiar LG, Villela N. et al. Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome. Atherosclerosis 2007; 195: 138-146.
• 110 Chen H, Montagnani M, Funahashi T. et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
• 111 Loomans CJ, de Koning EJ, Staal FJ. et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 2004; 53: 195-199.
• 112 Tepper OM, Galiano RD, Capla JM. et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 2002; 106: 2781-2786.
• 113 Liu ZJ, Velazquez OC. Hyperoxia, endothelial progenitor cell mobilization, and diabetic wound healing. Antioxid Redox Signal 2008; 10: 1869-1882.
• 114 Fadini GP, Miorin M, Facco M. et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol 2005; 45: 1449-1457.
• 115 Gallagher KA, Liu ZJ, Xiao M. et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117: 1249-1259.
• 116 Wu BJ, Midwinter RG, Cassano C. et al. Heme oxygenase-1 increases endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2009; 29: 1537-1542.
• 117 Sambuceti G, Morbelli S, Vanella L. et al. Diabetes impairs the vascular recruitment of normal stem cells by oxidant damage, reversed by increases in pAMPK, heme oxygenase-1, and adiponectin. Stem Cells 2009; 27: 399-407.
• 118 Peterson SJ, Husney D, Kruger AL. et al. Long-term treatment with the apolipo-protein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther 2007; 322: 514-520.